目的：探讨急性淋巴细胞白血病(all)与急性非淋巴细胞白血病(ANLL)AT M基因和BRCA2基因杂合性缺失及其相互关系。
Objective: To investigate the loss of heterozygosity (LOH) of ATM gene and BRCA2 gene and explore the relationship between two genes in patients with ALL and ANLL.
Rituxan现在已经被批准用于非霍奇金淋巴瘤、慢性淋巴细胞白血病和风湿性关节炎的治疗。
Rituxan is currently approved as a treatment for non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.
目的：探讨我院急性非淋巴细胞性白血病(ANLL)患者的治疗效果及其预后相关因素。
Objective: to investigated the therapy effect and prognosis related factors in the Acute Non-lymphocytic leukemia (ANLL) patients.
目的：为提高急性非淋巴细胞性白血病(急非淋)的疗效。
Objective To improve the therapeutic effect of acute non-lymphatic leukemia (ANLL).
目的：为提高急性非淋巴细胞性白血病(急非淋)的疗效。
Objective To improve the therapeutic effect of acute non-lymphatic leukemia (ANLL).
应用推荐